1. Academic Validation
  2. Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation

Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation

  • J Thromb Haemost. 2007 Dec;5(12):2461-6. doi: 10.1111/j.1538-7836.2007.02792.x.
E Hooley 1 P A McEwan J Emsley
Affiliations

Affiliation

  • 1 Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, UK.
Abstract

Background: Prekallikrein (PK) plays a central role in the contact system that activates blood coagulation and is involved in the regulation of blood pressure.

Objectives: To provide three-dimensional structural data for PK and rationalize the molecular basis of substrate recognition and zymogen activation.

Patients/methods: The PK homology model was constructed using the coagulation factor (F) XI crystal structure as a template with the program SWISS-MODEL.

Results: The domain organization of the PK apple domains and serine protease is conserved compared to FXI. Surface charge calculations on the PK model revealed that ligand binding to high-molecular-weight kininogen (HK) is predicted to have two key determinants: a pocket within the apple 2 domain and a basic channel formed at the interface of apple domains 1 and 4. A hereditary mutation resulting in PK deficiency (Gly104Arg) and the Lys140 alpha-kallikrein cleavage site both disrupt HK binding and are shown to map to opposite sides of the apple 2 domain pocket. The model also describes the differences in the apple 4 domain that prevents dimer formation in PK vs. FXI. A C-terminal extension in the PK serine protease domain is described as a potential substrate for prolylcarboxypeptidase.

Conclusions: The interaction between PK and HK is mediated by two discrete surfaces formed by the PK A1, A2 and A4 domains with charge likely to be a critical component of the binding. A novel mode of PK activation is postulated to involve prolylcarboxypeptidase cleaving at the C-terminus rather than the activation loop.

Figures